AURINIA PHARMACEUTICALS INC (AUPH)

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The firm has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Company Info

AURINIA PHARMACEUTICALS INC

#140, 14315 - 118 Avenue

Victoria BRITISH COLUMBIA V8Z 7X8

P: 12507442487

CEO: Peter Greenleaf

Employees: 300

Website: https://www.auriniapharma.com